{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:19:11Z","timestamp":1767831551634,"version":"3.49.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,7]],"date-time":"2021-02-07T00:00:00Z","timestamp":1612656000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.nmd.2021.02.001","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T11:09:27Z","timestamp":1612523367000},"page":"385-396","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Disease-modifying effects of edasalonexent, an NF-\u03baB inhibitor, in young boys with Duchenne muscular dystrophy: Results of the MoveDMD phase 2 and open label extension trial"],"prefix":"10.1016","volume":"31","author":[{"given":"Richard S.","family":"Finkel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Finanger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krista","family":"Vandenborne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Lee","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gihan","family":"Tennekoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Perry B.","family":"Shieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Willcocks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn","family":"Walter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William D.","family":"Rooney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean C.","family":"Forbes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William T.","family":"Triplett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina W.","family":"Yum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"MacDougall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelika","family":"Fretzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pradeep","family":"Bista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne M.","family":"Donovan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2021.02.001_bib0001","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.23528","article-title":"Evidence-based path to newborn screening for Duchenne muscular dystrophy","volume":"71","author":"Mendell","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2021.02.001_bib0002","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/ejhg.2012.301","article-title":"Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK)","volume":"21","author":"Moat","year":"2013","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.nmd.2021.02.001_bib0003","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.rehab.2013.06.002","article-title":"Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011","volume":"56","author":"Kieny","year":"2013","journal-title":"Ann Phys Rehabil Med"},{"key":"10.1016\/j.nmd.2021.02.001_bib0004","doi-asserted-by":"crossref","first-page":"299rv4","DOI":"10.1126\/scitranslmed.aaa7322","article-title":"Immune-mediated pathology in Duchenne muscular dystrophy","volume":"7","author":"Rosenberg","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.nmd.2021.02.001_bib0005","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1016\/j.biocel.2013.05.001","article-title":"Wasting mechanisms in muscular dystrophy","volume":"45","author":"Shin","year":"2013","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.nmd.2021.02.001_bib0006","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1172\/JCI30556","article-title":"Interplay of IKK\/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy","volume":"117","author":"Acharyya","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nmd.2021.02.001_bib0007","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00109-008-0373-8","article-title":"Nuclear factor-kappa B signaling in skeletal muscle atrophy","volume":"86","author":"Li","year":"2008","journal-title":"J Mol Med"},{"key":"10.1016\/j.nmd.2021.02.001_bib0008","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/B978-0-12-385940-2.00004-8","article-title":"NF-kappaB signaling in skeletal muscle health and disease","volume":"96","author":"Peterson","year":"2011","journal-title":"Curr Top Dev Biol"},{"key":"10.1016\/j.nmd.2021.02.001_bib0009","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1212\/01.wnl.0000173836.09176.c4","article-title":"Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy","volume":"65","author":"Chen","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.02.001_bib0010","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1096\/fj.02-0542com","article-title":"Mechanical stress activates the nuclear factor-kappaB pathway in skeletal muscle fibers: a possible role in Duchenne muscular dystrophy","volume":"17","author":"Kumar","year":"2003","journal-title":"FASEB J"},{"key":"10.1016\/j.nmd.2021.02.001_bib0011","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/mus.24607","article-title":"Musculoskeletal simulation can help explain selective muscle degeneration in Duchenne muscular dystrophy","volume":"52","author":"Hu","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2021.02.001_bib0012","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/hmg\/ddg197","article-title":"Dissection of temporal gene expression signatures of affected and spared muscle groups in dystrophin-deficient (mdx) mice","volume":"12","author":"Porter","year":"2003","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nmd.2021.02.001_bib0013","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.nmd.2013.12.012","article-title":"Longitudinal measurements of MRI-T2 in boys with Duchenne muscular dystrophy: effects of age and disease progression","volume":"24","author":"Willcocks","year":"2014","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2021.02.001_bib0014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106435","article-title":"Magnetic resonance imaging and spectroscopy assessment of lower extremity skeletal muscles in boys with Duchenne muscular dystrophy: a multicenter cross sectional study","volume":"9","author":"Forbes","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.nmd.2021.02.001_bib0015","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/mt.2011.261","article-title":"NF-kappaB negatively impacts the myogenic potential of muscle-derived stem cells","volume":"20","author":"Lu","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.nmd.2021.02.001_bib0016","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1172\/JCI28721","article-title":"Targeted ablation of IKK2 improves skeletal muscle strength, maintains mass, and promotes regeneration","volume":"116","author":"Mourkioti","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nmd.2021.02.001_bib0017","doi-asserted-by":"crossref","first-page":"e90341","DOI":"10.1172\/jci.insight.90341","article-title":"Disease-modifying effects of orally bioavailable NF-kappaB inhibitors in dystrophin-deficient muscle","volume":"1","author":"Hammers","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.nmd.2021.02.001_bib0018","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1021\/acs.jmedchem.5b01961","article-title":"Synthesis and Characterization of Fatty Acid Conjugates of Niacin and Salicylic Acid","volume":"59","author":"Vu","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.nmd.2021.02.001_bib0019","doi-asserted-by":"crossref","first-page":"e97957","DOI":"10.1371\/journal.pone.0097957","article-title":"Omega-3 free fatty acids suppress macrophage inflammasome activation by inhibiting NF-kappaB activation and enhancing autophagy","volume":"9","author":"Williams-Bey","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.nmd.2021.02.001_bib0020","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1359\/jbmr.091041","article-title":"Capacity of omega-3 fatty acids or eicosapentaenoic acid to counteract weightlessness-induced bone loss by inhibiting NF-kappaB activation: from cells to bed rest to astronauts","volume":"25","author":"Zwart","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.nmd.2021.02.001_bib0021","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1126\/science.8052854","article-title":"Inhibition of NF-kappa B by sodium salicylate and aspirin","volume":"265","author":"Kopp","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.nmd.2021.02.001_bib0022","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/23948","article-title":"The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta","volume":"396","author":"Yin","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.nmd.2021.02.001_bib0023","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/jcph.842","article-title":"A Novel NF-kappaB Inhibitor, Edasalonexent (CAT-1004), in development as a disease-modifying treatment for patients With Duchenne Muscular Dystrophy: phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in adult subjects","volume":"57","author":"Donovan","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.nmd.2021.02.001_bib0024","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3233\/JND-180341","article-title":"Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-kappaB Inhibitor, in Pediatric Patients with Duchenne Muscular Dystrophy","volume":"6","author":"Finanger","year":"2019","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2021.02.001_bib0025","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1212\/WNL.0000000000002337","article-title":"Practice guideline update summary: corticosteroid treatment of Duchenne muscular dystrophy: report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"86","author":"Gloss","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.02.001_bib0026","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/nbm.2851","article-title":"T(2) mapping provides multiple approaches for the characterization of muscle involvement in neuromuscular diseases: a cross-sectional study of lower leg muscles in 5-15-year-old boys with Duchenne muscular dystrophy","volume":"26","author":"Arpan","year":"2013","journal-title":"NMR Biomed"},{"key":"10.1016\/j.nmd.2021.02.001_bib0027","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/ana.24599","article-title":"Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort","volume":"79","author":"Willcocks","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2021.02.001_bib0028","doi-asserted-by":"crossref","first-page":"e897","DOI":"10.1212\/WNL.0000000000009012","article-title":"MR biomarkers predict clinical function in Duchenne muscular dystrophy","volume":"94","author":"Barnard","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.02.001_bib0029","doi-asserted-by":"crossref","first-page":"e1622","DOI":"10.1212\/WNL.0000000000009244","article-title":"Modeling disease trajectory in Duchenne muscular dystrophy","volume":"94","author":"Rooney","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.02.001_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194283","article-title":"Skeletal muscle magnetic resonance biomarkers correlate with function and sentinel events in Duchenne muscular dystrophy","volume":"13","author":"Barnard","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.nmd.2021.02.001_bib0031","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/mrm.24917","article-title":"Chemical shift-based MRI to measure fat fractions in dystrophic skeletal muscle","volume":"72","author":"Triplett","year":"2014","journal-title":"Magn Reson Med"},{"key":"10.1016\/j.nmd.2021.02.001_bib0032","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The molecular signatures database hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"key":"10.1016\/j.nmd.2021.02.001_bib0033","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.nmd.2019.09.010","article-title":"Longitudinal natural history in young boys with Duchenne muscular dystrophy","volume":"29","author":"Coratti","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2021.02.001_bib0034","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.4155\/cli.11.113","article-title":"Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings","volume":"1","author":"Bushby","year":"2011","journal-title":"Clin Investig"},{"key":"10.1016\/j.nmd.2021.02.001_bib0035","article-title":"The 6-minute walk test and person-reported outcomes in boys with Duchenne Muscular Dystrophy and typically developing controls: longitudinal comparisons and clinically-meaningful changes over one year","volume":"5","author":"Henricson","year":"2013","journal-title":"PLoS Curr"},{"key":"10.1016\/j.nmd.2021.02.001_bib0036","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.nmd.2010.06.014","article-title":"North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy","volume":"20","author":"Mazzone","year":"2010","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2021.02.001_bib0037","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1212\/WNL.0000000000000775","article-title":"Examination of effects of corticosteroids on skeletal muscles of boys with DMD using MRI and MRS","volume":"83","author":"Arpan","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.02.001_bib0038","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1007\/s00415-012-6512-8","article-title":"Permanent muscular sodium overload and persistent muscle edema in Duchenne muscular dystrophy: a possible contributor of progressive muscle degeneration","volume":"259","author":"Weber","year":"2012","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2021.02.001_bib0039","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/0022-510X(93)90052-Z","article-title":"Sodium is elevated in mdx muscles: ionic interactions in dystrophic cells","volume":"114","author":"Dunn","year":"1993","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.nmd.2021.02.001_bib0040","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1212\/WNL.31.3.331","article-title":"[Na+\u202f+\u202fK+] Mg2+-ATPase of muscle plasma membranes in Duchenne muscular dystrophy","volume":"31","author":"Niebroj-Dobosz","year":"1981","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.02.001_bib0041","doi-asserted-by":"crossref","first-page":"C1030","DOI":"10.1152\/ajpcell.00453.2019","article-title":"Isoform-specific Na,K-ATPase and membrane cholesterol remodeling in motor endplates in distinct mouse models of myodystrophy","volume":"318","author":"Kravtsova","year":"2020","journal-title":"Am. J. Physiol., Cell Physiol."},{"key":"10.1016\/j.nmd.2021.02.001_bib0042","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1113\/jphysiol.2005.087031","article-title":"Dexamethasone up-regulates skeletal muscle maximal Na+,K+ pump activity by muscle group specific mechanisms in humans","volume":"567","author":"Nordsborg","year":"2005","journal-title":"J Physiol"},{"key":"10.1016\/j.nmd.2021.02.001_bib0043","first-page":"2","article-title":"(23)Na MRI and myometry to compare eplerenone vs. glucocorticoid treatment in Duchenne dystrophy","volume":"36","author":"Glemser","year":"2017","journal-title":"Acta Myol"},{"key":"10.1016\/j.nmd.2021.02.001_bib0044","series-title":"Proceedings of the National Academy of Sciences of the United States of America","first-page":"7153","article-title":"Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy","volume":"112","author":"Hathout","year":"2015"},{"key":"10.1016\/j.nmd.2021.02.001_bib0045","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00246-012-0281-0","article-title":"Correlation of heart rate and cardiac dysfunction in Duchenne muscular dystrophy","volume":"33","author":"Thomas","year":"2012","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.nmd.2021.02.001_bib0046","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00246-014-1050-z","article-title":"Autonomic dysfunction: a driving force for myocardial fibrosis in young Duchenne muscular dystrophy patients?","volume":"36","author":"Thomas","year":"2015","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.nmd.2021.02.001_bib0047","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(10)62226-X","article-title":"Normal ranges of heart rate and respiratory rate in children from birth to 18 years of age: a systematic review of observational studies","volume":"377","author":"Fleming","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.nmd.2021.02.001_bib0048","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.pediatrneurol.2008.08.006","article-title":"High incidence of electrocardiogram abnormalities in young patients with Duchenne muscular dystrophy","volume":"39","author":"Takami","year":"2008","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.nmd.2021.02.001_bib0049","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1542\/peds.2010-0929","article-title":"Serum transaminase levels in boys with Duchenne and Becker muscular dystrophy","volume":"127","author":"McMillan","year":"2011","journal-title":"Pediatrics"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896621000304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896621000304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:10:41Z","timestamp":1760775041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896621000304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0960896621000304"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2021.02.001","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease-modifying effects of edasalonexent, an NF-\u03baB inhibitor, in young boys with Duchenne muscular dystrophy: Results of the MoveDMD phase 2 and open label extension trial","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2021.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}